Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$32.10K$32.10K−64.5% vs Q3 2018 Net Income-$138.58K-$138.58KN/M vs Q3 2018 EPS Diluted-$0.26-$0.26N/M vs Q3 2018 Gross Profit$24,090−69.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Operating Cash Flowderived-$48,780N/M Margins · derivedGross margin75.0%−11.0 pt vs Q3 2018
Operating margin-382.3%−85.2 pt vs Q3 2018
Net margin-431.7%−38.1 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 12, 2019 · 43 d after period end